Attachment B: 2012 Asthma Supplement Questions
This amount of space will be
occupied by the questionnaire title, OMB information, assurance of
confidentiality, introduction, and provider background information.
It is estimated that this supplement will take 15 minutes for the
provider to complete.
Background information:
A. Provider specialty
B. Census contact name
C. Provider serial number
D. Census contact telephone
Introduction: The National
Institutes of Health, Centers for Disease Control and Prevention,
and the US Environmental Protection Agency are conducting a special
survey on asthma care provided in community health centers and
private office settings. We are interested in the clinical
decisions you make about asthma. Please answer the following
questions about your actual practice. In responding, do not worry
about the ideal or “correct” answer. We appreciate your
time on this important public health concern.
1.0 For which of the following age groups do you see patients (don’t include patients of other practitioners at your site)?
Check all that apply:
□ children 0-12 years □ adolescents 12-21 years □ adults 18-64 years □ older adults 65 years and above
1.1 In your current practice, have you participated in an organized asthma improvement program that focused on improving quality of care or patient outcomes for patients with asthma?
□ yes □ no □ don’t know
1.2 Does your practice have an asthma registry? (an additional system often separate from medical records to track and manage only patients with asthma)?
□ yes □ no □ don’t know
1.3 Do you use a structured encounter form (i.e, an asthma template) when asthma is the primary reason for the visit?
□ yes, often □ yes, sometimes □ no □ don’t know
1.4 During your last normal week of practice, how many visits did you have with patients with asthma (don’t include patients of other practitioners at your site)?
________ Number of asthma visits □ don’t know
1.5 Consider a non-asthma visit with a patient with asthma. Which strategy below is closest to how you decide to address asthma?
□ I only address asthma when the patient raises a concern about asthma
□ I ask the patient about their asthma and I any specific concerns that the patient mentions
□ I ask the patient about their asthma and regardless of concerns, I fully review all aspects of asthma care
□ Regardless of the reason for the visit or patient concerns, I fully review all aspects of asthma care
1.6 How many of your patients (don’t include patients of other practitioners at your site) have:
Circle one number in each row. |
very few or none |
some patients |
about half of patients |
most patients |
all or nearly all patients |
Don’t know |
… asthma of mild severity? |
1 |
2 |
3 |
4 |
5 |
6 |
… asthma of moderate severity? |
1 |
2 |
3 |
4 |
5 |
6 |
… severe and/or difficult-to-control asthma? |
1 |
2 |
3 |
4 |
5 |
6 |
1.7 Are you notified by the hospital when one of your patients is admitted for asthma?
□ yes, in all or most cases □ yes, in some cases □ rarely or never □ don’t know
1.8 Are you notified by the hospital when one of your patients is seen in the emergency department for asthma?
□ yes, in all or most cases □ yes, in some cases □ rarely or never □ don’t know
2.1 How often do you use the following criteria to diagnose asthma?
Criteria: circle one number in each row. |
Rarely or never |
In some cases |
In about half of cases |
In most cases |
In all or nearly all cases |
1. History of recurrent cough, wheeze, chest tightness, difficulty breathing |
1 |
2 |
3 |
4 |
5 |
2. Worsening of symptoms in the presence of pollen, smoke, exercise, pets, or other specific exposures? |
1 |
2 |
3 |
4 |
5 |
3. Family history of asthma |
1 |
2 |
3 |
4 |
5 |
4. Physical exam findings |
1 |
2 |
3 |
4 |
5 |
5. Peak expiratory flow rate in your office |
1 |
2 |
3 |
4 |
5 |
6. Lung function testing/spirometry (in your office or by referral) |
1 |
2 |
3 |
4 |
5 |
7. Response to bronchodilators (e.g., Albuterol) |
1 |
2 |
3 |
4 |
5 |
8. Methacholine challenge |
1 |
2 |
3 |
4 |
5 |
9. Refer patients to a specialist for diagnosis |
1 |
2 |
3 |
4 |
5 |
10. Other (specify): |
1 |
2 |
3 |
4 |
5 |
The next two questions ask about your assessment of asthma severity and asthma control. Underlying severity is the intrinsic intensity of the disease process whereas asthma control is the degree to which asthma symptoms are minimized by therapy.
3.1 For patients for whom you make the initial diagnosis of asthma, do you make an initial severity assessment in order to determine the type and level of initial therapy needed?
□ yes □ no □ don’t know how to assess severity
3.2 Once a patient receives treatment, ongoing symptom patterns can show the degree to which a patient’s asthma is controlled. How frequently do you ask about the following symptoms or perform the following tests to assess asthma control?
Criteria: Circle one number in each row. |
Rarely or never |
In some cases |
In about half of cases |
In most cases |
In all or nearly all cases |
1. Ability to engage in normal daily activities |
1 |
2 |
3 |
4 |
5 |
2. Frequency of daytime symptoms |
1 |
2 |
3 |
4 |
5 |
3. Frequency of nighttime symptoms |
1 |
2 |
3 |
4 |
5 |
4. Patient perception of symptom control |
1 |
2 |
3 |
4 |
5 |
5. Control assessment tool e.g., Asthma Control Test (ACT) or Asthma Therapy Assessment Questionnaire (ATAQ) |
1 |
2 |
3 |
4 |
5 |
6. Patient symptom diaries |
1 |
2 |
3 |
4 |
5 |
7. Frequency of rescue inhaler use (such as Albuterol) |
1 |
2 |
3 |
4 |
5 |
8. Frequency of exacerbations requiring oral steroids |
1 |
2 |
3 |
4 |
5 |
9. Patient report of emergency department or urgent care visit for asthma |
1 |
2 |
3 |
4 |
5 |
10. Peak flow results at home |
1 |
2 |
3 |
4 |
5 |
11. Peak flow results in your office |
1 |
2 |
3 |
4 |
5 |
12 . Spriometry in the office |
1 |
2 |
3 |
4 |
5 |
4.1 How often do you use each of the following strategies to help patients control their asthma?
Circle one number in each row. |
Rarely or never |
In some cases |
In about half of cases |
In most cases |
In nearly all cases |
Not applicable |
1. Provide as asthma action plan (a written care plan that outlines medications, triggers, symptom management, and when to seek for emergent care)? |
1 |
2 |
3 |
4 |
5 |
n/a
|
Assessment by history of triggers at the patient’s… 2A. …home (e.g., pets, mold, second-hand smoke) 2B. …school (e.g., dust, fumes, exhaust) 2C …workplace (e.g., occupational exposures) |
1 1 1 |
2 2 2 |
3 3 3 |
4 4 4 |
5 5 5 |
n/a n/a n/a |
3.Specific assessment by history of triggers specific to individuals (e.g., exercise, weather, strong emotions) |
1 |
2 |
3 |
4 |
5 |
n/a |
4. Assessment of actual medication use (not filled prescriptions) |
1 |
2 |
3 |
4 |
5 |
n/a |
5. Education about avoiding/controlling triggers |
1 |
2 |
3 |
4 |
5 |
n/a |
6. Prescription of a spacer for short-acting beta agonist metered dose inhaler |
1 |
2 |
3 |
4 |
5 |
n/a |
7. Prescription of a spacer for inhaled corticosteroid metered dose inhaler |
1 |
2 |
3 |
4 |
5 |
n/a |
8. Regularly scheduled (non-urgent) asthma follow up visits to assess management |
1 |
2 |
3 |
4 |
5 |
n/a |
4.2 How often do you see patients for regularly scheduled (non-urgent) asthma visits in the following categories?
Circle one number in each row. |
No regular schedule |
Monthly or more frequently |
Every 3 months |
Every 6 months |
Yearly |
Not on controller medication with … 1A. … no exacerbations in past year 1B. … one exacerbation in the past year 1C … two or more exacerbations in the past year |
1 1 1 |
2 2 2 |
3 3 3 |
4 4 4 |
5 5 5 |
On controller medication with … 2A. … symptoms under control 2B. … symptoms not controlled |
1 1 |
2 2 |
3 3 |
4 4 |
5 5 |
4.3 How often do you make the following recommendations about environmental exposures that exist in a patient’s home?
Recommendation: circle one number in each row. |
For all asthma patients |
Only for patients with known or reported sensitivity to this trigger |
Rarely or never recommend |
|
1 |
2 |
3 |
2. HEPA air filtration (remove airborne allergens, mold, particulates) |
1 |
2 |
3 |
3. Controlling mold |
1 |
2 |
3 |
4. Controlling household pests (e.g. cockroaches, rodents) |
1 |
2 |
3 |
5. Removing pets from the home |
1 |
2 |
3 |
6. Avoiding pollen (e.g., limit outdoor time, close windows) |
1 |
2 |
3 |
7. Avoiding air pollution (e.g., limit outdoor time) |
1 |
2 |
3 |
8 Making changes to cooking appliances (e.g., stoves or exhaust vents) |
1 |
2 |
3 |
9. Avoiding second-hand tobacco smoke |
1 |
2 |
3 |
10.Other (specify): |
1 |
2 |
3 |
5.1 For children (0-17 years) with asthma, how do you use the following medications?
If you do not see patients in this age range, please skip to question 5.2
Medication: mark (x) for ALL that apply on each row. |
Do not use |
Rescue/for acute symptoms |
First line control therapy |
Add on control therapy if first line not effective |
For difficult to control asthma |
1. Short acting beta agonists (e.g. Albuterol) |
1 |
2 |
3 |
4 |
5 |
2.Inhaled corticosteroids (ICS) as a single agent |
1 |
2 |
3 |
4 |
5 |
3.Long acting beta agonists (LABA) (e.g., salmeterol/Serevent) as a single agent |
1 |
2 |
3 |
4 |
5 |
4. Combination medication that includes both LABA and ICS (e.g., fluticasone and salmeterol/Advair) |
1 |
2 |
3 |
4 |
5 |
5.Leukotriene modifiers (e.g., montelukast/Singulair) |
1 |
2 |
3 |
4 |
5 |
6.Methylxanthines (e.g., sustained-release theophylline) |
1 |
2 |
3 |
4 |
5 |
7.Immunotherpay (omalizumab/Xolair) |
1 |
2 |
3 |
4 |
5 |
8.Oral corticosteroids (short course ≤14 days) |
1 |
2 |
3 |
4 |
5 |
9.Oral corticosteroids (longer course >14 days) |
|
|
|
|
|
10.Other (specify): |
1 |
2 |
3 |
4 |
5 |
5.2 For adults (18 years and over) with asthma (how do you use the following medications?
If you do not see patients in this age range, please skip to question 6.1
Medication: mark (x) for ALL that apply on each row. |
Do not use |
Rescue/for acute symptoms |
First line control therapy |
Add on control therapy if first line not effective |
For difficult to control asthma |
1. Short acting beta agonists (e.g. Albuterol) |
1 |
2 |
3 |
4 |
5 |
2.Inhaled corticosteroids (ICS) as a single agent |
1 |
2 |
3 |
4 |
5 |
3.Long acting beta agonists (LABA) (e.g., salmeterol/Serevent) as a single agent |
1 |
2 |
3 |
4 |
5 |
4. Combination medication that includes both LABA and ICS (e.g. fluticasone and salmeterol/Advair) |
1 |
2 |
3 |
4 |
5 |
5.Leukotriene modifiers (e.g., montelukast/Singulair) |
1 |
2 |
3 |
4 |
5 |
6.Methylxanthines (e.g., sustained-release theophylline) |
1 |
2 |
3 |
4 |
5 |
7. Immunotherpay (omalizumab/Xolair) |
1 |
2 |
3 |
4 |
5 |
8.Oral corticosteroids (short course ≤14 days) |
1 |
2 |
3 |
4 |
5 |
9.Oral corticosteroids (longer course >14 days) |
|
|
|
|
|
9.Other (specify): |
1 |
2 |
3 |
4 |
5 |
6.1 Below are several strategies and tools that could be used to help patients control their asthma. First specify if you use each strategy, and next, specify the most important barrier (if any) you face to using each strategy.
|
Do you use this strategy? |
No barrier |
Poor patient adherence |
Poor patient health literacy |
Lack of staff/equipment |
Lack of MD training |
Lack of time |
Lack of payment |
|
|
Choose yes or no |
Circle one |
|||||||
1. Using written asthma action plans |
YES
|
NO
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
2. Using home peak flow monitors |
YES
|
NO
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
3.Performing in-office spirometry |
YES
|
NO
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
4. Educating patients to recognize worsening asthma |
YES
|
NO
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
5. Educating patients on avoiding risk factors or triggers |
YES
|
NO
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
6. Involving patients in treatment decision-making |
YES
|
NO
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
7. Teaching inhaler technique |
YES
|
NO
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8. Observing inhaler use by patient |
YES
|
NO
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
9. Advising patients on changes to home environment |
YES
|
NO
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
10. Advising patients on changes to work environment |
YES
|
NO
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
6.2 Which, if any of the following concerns about prescribing inhaled corticosteroids to patients with persistent asthma do you have?
|
Is this a concern? |
Does this concern ever prevent you from prescribing inhaled corticosteroids? |
No concerns about lower doses, but concerned with side effects at higher doses |
YES NO |
YES NO |
Concerned about long-term side effects with continued use (e.g., cataracts, bone loss, delayed growth in children) |
YES NO |
YES NO |
Concerned about patient confusion between rescue and control medications |
YES NO |
YES NO |
Concerned about patient non-acceptance |
YES NO |
YES NO |
Other:
|
YES NO |
YES NO |
6.3 How often, if ever, do you encounter these patient concerns or misunderstandings about inhaled corticosteroids?
Circle one number in each row. |
Do not encounter |
Rarely |
Sometimes |
Often |
1. Short-term side effects (such as thrush) |
1 |
2 |
3 |
4 |
2. Long-term side effects (such as bone loss, cataracts, delayed growth in children) |
1 |
2 |
3 |
4 |
3. Misunderstanding of risks or side effects, or belief in myths (e.g., muscle development, aggression, addiction) |
1 |
2 |
3 |
4 |
4. Confusion between rescue medication and controller medication |
1 |
2 |
3 |
4 |
6. Other (specify): |
1 |
2 |
3 |
4 |
7.1 Indicate which of the following ways, if any, you have learned about the asthma guidelines (check all that apply)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.0 Who completed this survey?
□ the physician to whom it was addressed □ office staff □ other
CLOSING STATEMENT
Thank you for completing this special survey. We appreciate your time and effort.
The following proposed screener question will be added to the 2012 NAMCS induction interview form. The purpose of this question will be to determine asthma supplement eligibility.
“Do any of the patients you treat have asthma?”
File Type | application/msword |
File Title | Include 4 components with emphasis on 6 GIP messages: |
Author | lea8 |
Last Modified By | zgl7 |
File Modified | 2011-01-13 |
File Created | 2011-01-11 |